XRAY: Director Mazelsky Acquires 2,638 Phantom Shares May 22, 2026

Insider trading can reveal what company leaders really think about their business. When executives buy shares, it often signals confidence. Today we’re looking at a significant insider transaction at XRAY (DENTSPLY SIRONA Inc.), where director Jonathan Jay Mazelsky acquired phantom stock through the company’s deferred compensation plan. This award-based transaction shows continued executive engagement with the dental equipment manufacturer. Let’s break down what this insider move means for shareholders.

Director Phantom Stock Award at DENTSPLY SIRONA

Jonathan Jay Mazelsky, a director at DENTSPLY SIRONA, received an award of phantom stock on December 31, 2025. The transaction involved acquiring 2,638 shares of phantom stock through the company’s Directors’ Deferred Compensation (DDC) plan. This is not a cash purchase but rather a compensation award granted to board members.

Phantom stock represents a contractual right to receive cash equal to the value of actual shares at a future date. Directors often receive these awards as part of their board compensation packages. After this transaction, Mazelsky held 14,382 total phantom stock units in his deferred compensation account.

Understanding the Form 4 Filing and Award Transaction

The SEC filing was submitted on January 2, 2026, reporting the December 31 transaction. Form 4 filings disclose changes in insider ownership within two business days of the transaction. The transaction type code “A-Award” indicates this was a grant or award, not a market purchase.

This filing shows Mazelsky’s growing stake in phantom stock compensation. The award mechanism allows directors to defer compensation and build equity exposure without immediate cash outlay. Such awards demonstrate the company’s commitment to aligning director interests with shareholder value.

What This Insider Activity Signals

Director compensation awards like this one are routine governance practices at public companies. They reflect DENTSPLY SIRONA’s structured approach to board compensation and retention. The phantom stock mechanism lets directors participate in company performance while maintaining flexibility in compensation timing.

Meyka AI rates XRAY a grade of B, reflecting solid fundamentals in the dental equipment sector. This insider transaction, while routine, adds to the overall picture of management engagement. Continued director participation in compensation plans suggests confidence in the company’s long-term direction and strategy.

Phantom Stock vs. Real Shares: Key Differences

Phantom stock differs fundamentally from actual equity ownership. Directors receive cash payments based on phantom stock value rather than voting rights or direct ownership. This structure provides compensation flexibility while limiting dilution to existing shareholders.

The DDC plan allows DENTSPLY SIRONA to offer competitive board compensation without issuing new shares. Mazelsky’s 14,382 phantom units represent significant deferred compensation value. This arrangement aligns director interests with company performance while maintaining clean cap table management.

Final Thoughts

Director Jonathan Jay Mazelsky’s acquisition of 2,638 phantom stock units through DENTSPLY SIRONA’s deferred compensation plan reflects routine board compensation practices. This award-based transaction shows continued executive engagement with the company’s governance structure. While phantom stock awards differ from direct share purchases, they demonstrate management’s commitment to aligning compensation with company performance. The filing reinforces DENTSPLY SIRONA’s structured approach to director retention and incentive alignment in the competitive dental equipment market.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.